Braizon Therapeutics, Inc
Braizon Therapeutics, a Japanese venture capital backed biotechnology company, is commercializing a unique and innovative technology for the delivery of drugs into the central nervous system (CNS) via the blood brain barrier (BBB). This platform technology encapsulates a wide variety of drug modalities, removing a significant development challenge for the many potential CNS drugs that cannot cross the BBB, including antibodies and nucleic acid medicines.
Braizon is working with pharmaceutical companies globally to bring their developments for CNS disorders to the clinic with our targeted and efficient drug delivery system. Leveraging the power of this technology Braizon will also develop novel academic discoveries into clinical stage assets to accelerate new therapy options for the many unmet medical needs in this increasingly important area.
- Mariko Tosu, PhD CEO and President